BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
土曜日, 9 26

MBX Biosciences Inc

MBXNASDAQ
Trade with Public
Trade with Public
$53.63
-1.76-3.18%
近くで: Sep 25, 5:00 PM EST
$53.63
N/A
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

MBX Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for MBX Biosciences (MBX).

Price Target Range — 7 Quarters

Analyst Consensus — 13 Analysts

2S.Buy
10Buy
1Sell
Consensus RatingBuy# Analysts13Avg. Consensus PT$64Upside to Avg. PT+18.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026JP MorganJessica FyeReinstatesOverweight$88
Aug 10, 2026Truist SecuritiesSrikripa DevarakondaPT RaiseBuy$70→$88
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86

Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $50 to $70.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved